The total cost of HPV-related diseases accounts for €200–250 million of which €210 million is absorbed by the prevention and treatment of precancerous lesions and cervical cancer. Although both available HPV vaccines are below the threshold value for economic convenience (€9,569 and €26,361 per QALY-gained for the quadrivalent and bivalent vaccines, respectively), at this point in time long-term economic models developed for Italy seem to indicate the quadrivalent vaccine as the most cost-effective option. Recent publications by official bodies, including the World Health Organization and the Supervisory Authority for Public Contracts in Italy, recommend that the decision-making process be based on both the quality of goods and services as well as the best achievable price.
Mennini, F.s., Costa, S., Favato, G., Picardo, M. (2009). Anti-HPV vaccination in Italy: a review of recent economic data for Italy. VACCINE, 27(S1), A54-A61 [10.1016/j.vaccine.2009.02.052].
Anti-HPV vaccination in Italy: a review of recent economic data for Italy
MENNINI, FRANCESCO SAVERIO;
2009-05-01
Abstract
The total cost of HPV-related diseases accounts for €200–250 million of which €210 million is absorbed by the prevention and treatment of precancerous lesions and cervical cancer. Although both available HPV vaccines are below the threshold value for economic convenience (€9,569 and €26,361 per QALY-gained for the quadrivalent and bivalent vaccines, respectively), at this point in time long-term economic models developed for Italy seem to indicate the quadrivalent vaccine as the most cost-effective option. Recent publications by official bodies, including the World Health Organization and the Supervisory Authority for Public Contracts in Italy, recommend that the decision-making process be based on both the quality of goods and services as well as the best achievable price.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
